369 related articles for article (PubMed ID: 26697993)
1. Musculoskeletal manifestations of Fabry disease: A retrospective study.
Lidove O; Zeller V; Chicheportiche V; Meyssonnier V; Sené T; Godot S; Ziza JM
Joint Bone Spine; 2016 Jul; 83(4):421-6. PubMed ID: 26697993
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease in children: a federal screening programme in Russia.
Namazova-Baranova LS; Baranov AA; Pushkov AA; Savostyanov KV
Eur J Pediatr; 2017 Oct; 176(10):1385-1391. PubMed ID: 28871487
[TBL] [Abstract][Full Text] [Related]
3. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.
Ries M; Ramaswami U; Parini R; Lindblad B; Whybra C; Willers I; Gal A; Beck M
Eur J Pediatr; 2003 Nov; 162(11):767-72. PubMed ID: 14505049
[TBL] [Abstract][Full Text] [Related]
4. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
5. The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study.
Turkmen K; Guclu A; Sahin G; Kocyigit I; Demirtas L; Erdur FM; Sengül E; Ozkan O; Emre H; Turgut F; Unal H; Karaman M; Acıkel C; Esen H; Balli E; Bıtırgen G; Tonbul HZ; Yılmaz MI; Ortiz A
Kidney Blood Press Res; 2016; 41(6):1016-1024. PubMed ID: 28006774
[TBL] [Abstract][Full Text] [Related]
6. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up].
Lidove O; Bekri S; Goizet C; Khau Van Kien A; Aractingi S; Knebelmann B; Choukroun G; Tsimaratos M; Redonnet-Vernhet I; Lacombe D; Jaussaud R
Presse Med; 2007; 36(7-8):1084-97. PubMed ID: 17276649
[TBL] [Abstract][Full Text] [Related]
7. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
Sims K; Politei J; Banikazemi M; Lee P
Stroke; 2009 Mar; 40(3):788-94. PubMed ID: 19150871
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
9. Musculoskeletal problems in pediatric acute leukemia.
Riccio I; Marcarelli M; Del Regno N; Fusco C; Di Martino M; Savarese R; Gualdiero G; Oreste M; Indolfi C; Porpora G; Esposito M; Casale F; Riccardi G
J Pediatr Orthop B; 2013 May; 22(3):264-9. PubMed ID: 23407432
[TBL] [Abstract][Full Text] [Related]
10. The evolution of the initial manifestations and renal involvement of chinese patients with classical and late-onset Fabry disease at different sexes and ages.
Guo W; Xie Y; Ji P; Li S; Cai G; Chen X
BMC Nephrol; 2023 Apr; 24(1):90. PubMed ID: 37020293
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
Mehta A; Ricci R; Widmer U; Dehout F; Garcia de Lorenzo A; Kampmann C; Linhart A; Sunder-Plassmann G; Ries M; Beck M
Eur J Clin Invest; 2004 Mar; 34(3):236-42. PubMed ID: 15025684
[TBL] [Abstract][Full Text] [Related]
12. Distal extremity pain as a presenting feature of Fabry's disease.
Pagnini I; Borsini W; Cecchi F; Sgalambro A; Olivotto I; Frullini A; Cimaz R
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):390-5. PubMed ID: 20981813
[TBL] [Abstract][Full Text] [Related]
13. Neurological complications of Anderson-Fabry disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease and the skin: data from FOS, the Fabry outcome survey.
Orteu CH; Jansen T; Lidove O; Jaussaud R; Hughes DA; Pintos-Morell G; Ramaswami U; Parini R; Sunder-Plassman G; Beck M; Mehta AB;
Br J Dermatol; 2007 Aug; 157(2):331-7. PubMed ID: 17573884
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for diagnosis, therapy and follow up of Anderson-Fabry disease.
Kes VB; Cesarik M; Zavoreo I; Soldo-Butković S; Kes P; Basić-Jukić N; Racki S; Jakić M; Delić-Brkljacić D; Jukić Z; Trkanjec Z; Serić V; Solter VV; Bielen I; Basić S; Demarin V; ; ; ;
Acta Clin Croat; 2013 Sep; 52(3):395-405. PubMed ID: 24558776
[TBL] [Abstract][Full Text] [Related]
17. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines for diagnosis, therapy and follow up of Anderson-Fabry disease].
Kes VB; Cesarik M; Zavoreo I; Butković SS; Kes P; Bašić-Jukić N; Rački S; Jakić M; Delić-Brkljačić D; Jukić Z; Trkanjec Z; Šerić V; Solter VV; Bielen I; Bašić S; Demarin V; ; ; ;
Acta Med Croatica; 2014 Apr; 68(2):223-32. PubMed ID: 26012164
[TBL] [Abstract][Full Text] [Related]
19. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
Vedder AC; Linthorst GE; van Breemen MJ; Groener JE; Bemelman FJ; Strijland A; Mannens MM; Aerts JM; Hollak CE
J Inherit Metab Dis; 2007 Feb; 30(1):68-78. PubMed ID: 17206462
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
